SCHEMBL22026435

SCHEMBL22026435

NNC(=O)NCc1cccc(O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
PKM P14618 1/20 0.62
ALOX15 P16050 1/20 0.62
NFKB1 P19838 1/20 0.62
MAPK1 P28482 1/20 0.62
KDM4E B2RXH2 2/20 0.61
MAPT P10636 2/20 0.61
KMT2A Q03164 1/20 0.61
LMNA P02545 1/20 0.61
BLM P54132 1/20 0.61
PMP22 Q01453 1/20 0.61
ALDH1A1 P00352 1/20 0.51
ROCK2 O75116 2/20 0.50
ROCK1 Q13464 2/20 0.50
HIF1A Q16665 1/20 0.50
SRC P12931 1/20 0.49
ENPP2 Q13822 1/20 0.48
GABRP O00591 1/20 0.47
GABRD O14764 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15431479 0.89 MAPT (0.54) CYP1A2CYP3A4PKMALOX15NFKB1
SCHEMBL14289839 0.83 CYP1A2 (0.53) CYP1A2CYP3A4PKMALOX15NFKB1
SCHEMBL358332 0.82 CYP1A2 (0.61) CYP1A2CYP3A4PKMALOX15NFKB1
SCHEMBL8178554 0.81 ANPEP (0.54) MAPK1LMNAROCK2ROCK1SRC
SCHEMBL2806074 0.80 CYP1A2 (0.59) CYP1A2CYP3A4PKMALOX15NFKB1
SCHEMBL3062841 0.80 EPHX1 (0.61) CYP1A2KDM4EMAPTKMT2ALMNA
SCHEMBL4893863 0.79 EPHX1 (0.49) CYP1A2CYP3A4PKMALOX15NFKB1
SCHEMBL18722706 0.79 CYP1A2 (0.56) CYP1A2CYP3A4PKMALOX15NFKB1
SCHEMBL31724652 0.79 CYP1A2 (0.56) CYP1A2CYP3A4PKMALOX15NFKB1
SCHEMBL5725833 0.79 CYP1A2 (0.56) CYP1A2CYP3A4PKMALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020158840-A1 ANTI-CANCER AGENT 日産化学株式会社 2020-08-06 WO disclosed
US-20200165194-A1 ADDITIVE COMPOSITION FOR CULTURE MEDIUM, ADDITIVE COMPOUND FOR CULTURE MEDIUM, AND METHOD FOR CULTURE OF CELLS OR TISSUE USING SAME NISSAN CHEMICAL CORPORATION (JP) 2020-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200165194-A1 ADDITIVE COMPOSITION FOR CULTURE MEDIUM, ADDITIVE COMPOUND FOR CULTURE MEDIUM, AND METHOD FOR CULTURE OF CELLS OR TISSUE USING SAME NEFM, FGF2, FGF1 CYP1A2 3961/4885CYP3A4 4142/4885PKM 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.